Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy

被引:58
作者
Terwee, CB
Prummel, MF
Gerding, MN
Kahaly, GJ
Dekker, FW
Wiersinga, WM
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1012 WX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1012 WX Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RA Leiden, Netherlands
[4] Gutenberg Univ Hosp, Dept Endocrinol Metab, Mainz, Germany
关键词
D O I
10.1111/j.1365-2265.2005.02186.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The concept of disease activity in Graves' ophthalmopathy (GO) might explain why as many as one-third of patients do not respond to immunosuppressive treatment, because only patients in the active stage of disease are expected to respond. The hypothesis was adopted that a parameter used to measure disease activity should be able to predict a response to immunosuppressive treatment. The aim of this study was to develop a multivariate prediction model in which all previous tested activity parameters are integrated. Design and Patients We included 66 consecutive patients with untreated moderately severe GO who had been euthyroid for at least 2 months. All patients were treated with radiotherapy. Measurements Treatment efficacy after 6 months follow-up was used as the primary outcome measure. Disease severity and 15 different disease activity parameters were assessed before treatment. Univariate and multivariate logistic regression models were used to predict response (model 1) or no change (model 2). Results In multivariate analyses, we found that duration of GO, soft tissue involvement, elevation, soluble interleukin-2 receptor (sIL-2R), soluble CD30 (sCD30), eye muscle reflectivity and octreotide uptake ratio were significant predictors of a response to radiotherapy. Gender, duration of GO, soft tissue involvement, eye muscle reflectivity, IL-6 and urinary glycosaminoglycan (GAG) excretion were significant predictors of no change upon radiotherapy. Prognostic score charts were developed for use in clinical practice to calculate the probability of response (model 1) and the probability of no change (model 2) for each new patient. Finally we used a combination of both models to define a recommended treatment modality for each individual patient, based on both the predicted probabilities of response and no change. We were able to identify the correct treatment (based on a comparison with the observed response) in 89% of the patients. Conclusions Although we strongly recommend that our results should be confirmed in other studies, our findings are the first evidence for the idea that disease (in)activity should determine which kind of treatment should be used.
引用
收藏
页码:145 / 155
页数:11
相关论文
共 33 条
[1]   CHOICE OF THERAPY AND CRITERIA FOR ASSESSING TREATMENT OUTCOME IN THYROID-ASSOCIATED OPHTHALMOPATHY [J].
BAHN, RS ;
GORMAN, CA .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (02) :391-407
[2]   Management of Graves' ophthalmopathy: Reality and perspectives [J].
Bartalena, L ;
Pinchera, A ;
Marcocci, C .
ENDOCRINE REVIEWS, 2000, 21 (02) :168-199
[3]   ORBITAL COBALT IRRADIATION COMBINED WITH SYSTEMIC CORTICOSTEROIDS FOR GRAVES OPHTHALMOPATHY - COMPARISON WITH SYSTEMIC CORTICOSTEROIDS ALONE [J].
BARTALENA, L ;
MARCOCCI, C ;
CHIOVATO, L ;
LADDAGA, M ;
LEPRI, G ;
ANDREANI, D ;
CAVALLACCI, G ;
BASCHIERI, L ;
PINCHERA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (06) :1139-1144
[4]   Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy [J].
Colao, A ;
Lastoria, S ;
Ferone, D ;
Pivonello, R ;
Macchia, PE ;
Vassallo, P ;
Bonavolontá, G ;
Muto, P ;
Lombardi, G ;
Fenzi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3790-3794
[5]  
DUKEELDER S, 1962, FDN OPHTHALMOLOGY HE, P370
[6]   Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy [J].
Gerding, MM ;
van der Zant, FM ;
van Royen, EA ;
Koornneef, L ;
Krenning, EP ;
Wiersinga, WM ;
Prummel, MF .
CLINICAL ENDOCRINOLOGY, 1999, 50 (03) :373-379
[7]   The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy [J].
Gerding, MN ;
Prummel, MF ;
Kalmann, R ;
Koornneef, L ;
Wiersinga, WM .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (07) :459-462
[8]   Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters [J].
Gerding, MN ;
Prummel, MF ;
Wiersinga, WM .
CLINICAL ENDOCRINOLOGY, 2000, 52 (05) :641-646
[9]   Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy [J].
Gerding, MN ;
van der Meer, JWC ;
Broenink, M ;
Bakker, O ;
Wiersinga, WM ;
Prummel, MF .
CLINICAL ENDOCRINOLOGY, 2000, 52 (03) :267-271
[10]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36